Abstract: The present invention relates to the use of type III polyketide synthases of bacteria, such as actinomycete bacteria, as phloroglucinol synthases. The present invention also relates to the isolated nucleic acid molecules encoding these type III polyketide synthases, and also to the vectors and the host cells comprising such nucleic acid molecules. The present invention also relates to methods for producing phloroglucinol.

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Abstract: The present application concerns a high-voltage circuit breaker filled with insulating gas having a main axis A, including arcing contacts and an insulating nozzle, wherein an insulating gas flowing from a storage chamber and heated by an electric arc between the two arcing contacts is partitioned into a first gas flow and a second gas flow conducted outside of the insulating nozzle from opposite directions toward a main gas chamber, wherein the first gas flow flows through a first intermediary gas chamber and the second gas flow flows through a second intermediary gas chamber and is partitioned in a first portion directed to the main gas chamber and a second portion directed to an exhaust gas chamber, characterized in that the first portion of the second gas flow is smaller than the second portion of the second gas flow.

Abstract: The present application concerns a circuit breaker including a movable contact, a driving rod slidably mounted in the circuit breaker, a linkage mechanism for driving the movable contact, a pivoted driving fork rotatably mounted in the circuit breaker which cooperates with the driving rod through the cooperation of a primary pin provided on the driving rod and a primary slot provided on the driving fork, a driven lever connecting the driving fork to the movable contact, and wherein the driving rod supports a secondary pin which cooperates with a secondary slot of the driving fork when the driving rod in a position between a predetermined position and an extreme opened position of the circuit breaker.

Abstract: The present invention relates to the field of bio-production of ectoine. There is a need in the art for ectoine production methods allowing its highly efficient synthesis and secretion. The solution proposed in the present invention is the use of a genetically modified yeast comprising many modifications as described in the present text.

Abstract: A filter system and clamp system for a gas turbine air inlet uses a single clamp system that allows for securing in place both a first element and a second element on the grid of the gas turbine air inlet. The clamp system can be released to allow for services of the first filter element, while the second filter element remains in sealing engagement with the grid.

Abstract: Metabolites produced by a microorganism using oxaloacetate, pyruvate and/or acetyl-CoA as substrate or co-substrate upstream in the biosynthesis pathway, and more particularly using oxaloacetate. There is indeed a need in the art for transformed, in particular recombinant, microorganisms having at least an increased ability to produce oxaloacetate, pyruvate and/or acetyl-CoA, and in particular oxaloacetate, thus allowing an increased capacity to produce metabolites produced using oxaloacetate, pyruvate and/or acetyl-CoA as substrate or co-substrate upstream in the biosynthesis pathway, and in particular amino acids and their derivatives thereof, fatty acids, derivatives from the mevalonate pathway (in particular farnesyl, squalene, lanosterol, cholesterol and derivatives, and dolichols), flavonoides and/or polyketides. The solution proposed is the use of a genetically modified yeast comprising many modifications as described in the present text.

Abstract: A method for the bio-production of threonine including genetically modified yeasts and a method in which they are used to produce threonine, as compared to the parent yeasts.

Abstract: The present disclosure provides recombinant microorganisms and methods for producing malonate semialdehyde and/or related products, such as ketones, alcohols, organic acids, esters, alkenes, amino acids, and combinations thereof including 3-hydroxypropionic acid, acrylic acid, propionic acid, 1-propanol, acetone, 2-propanol, butanone, 1-butanol, 2-butanol, methyl propionate, 1,3-propanediol, isoamyl alcohol, 1,3-butanediol, 1,4-butanediol, 2,3-butanediol, lactic acid, adipic acid, glutamic acid, itaconic acid, ethyl acetate, isopropyl acetate, acetic acid, butyric acid, caproic acid, citric acid, methacrylic acid, succinic acid, propylene, butadiene, ethanol, isoprenol, leucine, isoleucine, glutamine, glycine, and isoprene, from ?-alanine. The recombinant microorganism expresses an asparate 1-decarboxylase that catalyzes the production of malonate semialdehyde from ?-alanine.

Abstract: Methods for producing phloroglucinol as well as methods of using type III polyketide synthases as phloroglucinol synthases, in particular the type III polyketide synthases of algae, such as eukaryotic ochrophyte algae, are described herein. In addition, polypeptides that have phloroglucinol synthase activity, the isolated nucleic acid molecules encoding these type III polyketide synthases, and the vectors and the host cells comprising such nucleic acid molecules are also described.

Abstract: Metabolites produced by a microorganism using more particularly oxaloacetate as substrate or co-substrate upstream in the biosynthesis pathway. There is indeed a need in the art for transformed, in particular recombinant, microorganisms having at least an increased ability to produce oxaloacetate, thus allowing an increased capacity to produce oxaloacetate-derived amino acids and amino acid derivatives, the oxaloacetate-derived amino acids and amino acid derivatives being termed oxaloacetate derivatives. The solution is the use of a genetically modified yeast including many modifications as described in the present text.

Abstract: The present invention relates to a living cell, preferably a host cell, that is phloroglucinol resistant, said host cell being characterized in that it overexpresses a polypeptide selected from (i) transmembrane transporters of the ABC family, in particular transmembrane transporters of the PDR subfamily, (ii) transcription factors which control the expression of the transmembrane transporters of the PDR subfamily, and (iii) transmembrane transporters of the MFS family; preferably a polypeptide selected from SNQ2, STE6, PDR3, AQR1, DTR1, FLR1, QDR1, YHK8 and ATR1; and more preferably the SNQ2 transporter. The present invention also relates to a method for producing a phloroglucinol-resistant recombinant host cell. The present invention also relates to a method for producing phloroglucinol.

Abstract: The present invention relates to a recombinant yeast, in the genome of which at least one nucleic acid encoding an enzyme able to catalyze the decarboxylation of oxaloacetate into malonic semi-aldehyde, or one of its salts is overexpressed and/or under the control of a strong or inducible promoter. The invention also relates to such an enzyme per se, as well as to a method for producing malonic semi-aldehyde, one of its salts, or a malonic semi-aldehyde derivative comprising implementing the said recombinant yeast and to the use of the said recombinant yeast for the production of malonic semi-aldehyde, one of its salts, or a malonic semi-aldehyde derivative.

Abstract: A method of the bio-production of methionine and/or of its derivatives thereof from a reduced source of sulfur, such as MeSH or MeSNa including genetically modified yeasts, having an increased ability to produce methionine and/or its derivatives thereof, as compared to the parent yeasts.

Abstract: The present invention relates to the field of bio-production of ectoine. There is a need in the art for ectoine production methods allowing its highly efficient synthesis and secretion. The solution proposed in the present invention is the use of a genetically modified yeast comprising many modifications as described in the present text.

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Abstract: The present invention relates to the use of type III polyketide synthases of bacteria, such as actinomycete bacteria, as phloroglucinol synthases. The present invention also relates to the isolated nucleic acid molecules encoding these type III polyketide synthases, and also to the vectors and the host cells comprising such nucleic acid molecules. The present invention also relates to methods for producing phloroglucinol.

Abstract: A method for the bio-production of threonine including genetically modified yeasts and a method in which they are used to produce threonine, as compared to the parent yeasts.

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Abstract: Metabolites produced by a microorganism using more particularly oxaloacetate as substrate or co-substrate upstream in the biosynthesis pathway. There is indeed a need in the art for transformed, in particular recombinant, microorganisms having at least an increased ability to produce oxaloacetate, thus allowing an increased capacity to produce oxaloacetate-derived amino acids and amino acid derivatives, the oxaloacetate-derived amino acids and amino acid derivatives being termed oxaloacetate derivatives. The solution is the use of a genetically modified yeast including many modifications as described in the present text.